 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Ribozyme Pharmaceuticals, Inc.
 |
Ribozyme Pharmaceuticals, Inc. |
 |
 |
 |
PROFILE |
 |
Ribozyme Pharmaceuticals knows that too much protein can sometimes be a bad thing. The company is developing human ribozyme therapies for diseases caused by the overproduction of damaging proteins. Ribozymes, a form of RNA, inhibit protein production. The firm and partner Chiron are developing lead product candidate Angiozyme as a potential treatment for solid tumors. The company is also developing treatments for hepatitis B and C, and it is developing Herzyme, which may treat breast and other cancers, through Medizyme Pharmaceuticals, a joint venture with Elan (which owns almost 15% of Ribozyme). Ribozyme owns about 30% of Atugen, which provides drug target discovery and validation services.
COMPETITION |
 |
Agouron Pharmaceuticals, Inc. (dossier)
Isis Pharmaceuticals, Inc. (ISIP)
Ribapharm Inc. (dossier)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 15.50
1-Yr. Sales Growth: 101.3%
Employees: 113
Revenue per employee: $137,168.14
KEY PEOPLE |
 |
Howard W. Robin
CEO
Marvin Tancer
CFO
CONTACT INFO |
 |
2950 Wilderness Place
Boulder, CO 80301
US
Phone: 303-449-6500
Fax: 303-449-6995
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |